Afya (NASDAQ:AFYA) Downgraded by Zacks Investment Research to Hold

Last updated on Thursday, July 22, 2021 | 2021 MarketBeat

Afya (NASDAQ:AFYA) was downgraded by Zacks Investment Research from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Thursday, reports.

According to Zacks, "Afya Limited is a medical education group primarily in Brazil. Afya Limited is based in NEW YORK. "

A number of other equities analysts have also issued reports on the stock. Morgan Stanley lowered shares of Afya from an "overweight" rating to an "equal weight" rating and reduced their price target for the stock from $32.00 to $28.50 in a research report on Wednesday. UBS Group raised shares of Afya from a "neutral" rating to a "buy" rating in a research report on Thursday, April 15th. Finally, TheStreet raised shares of Afya from a "d+" rating to a "c-" rating in a research note on Monday, June 14th. Three research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. The company has a consensus rating of "Buy" and a consensus target price of $29.78.

Shares of NASDAQ:AFYA traded down $0.41 during trading on Thursday, reaching $23.78. The stock had a trading volume of 3,642 shares, compared to its average volume of 115,870. The firm has a market cap of $2.22 billion, a P/E ratio of 39.63, a P/E/G ratio of 1.03 and a beta of 1.33. The company has a debt-to-equity ratio of 0.17, a current ratio of 2.12 and a quick ratio of 2.10. The stock has a 50-day moving average of $24.98. Afya has a one year low of $18.48 and a one year high of $29.01.

Afya (NASDAQ:AFYA) last announced its quarterly earnings data on Wednesday, May 26th. The company reported $1.16 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $1.56 by ($0.40). The company had revenue of $72.15 million during the quarter, compared to analysts' expectations of $72.96 million. Afya had a net margin of 22.99% and a return on equity of 11.73%. As a group, analysts forecast that Afya will post 0.99 earnings per share for the current year.

A number of institutional investors and hedge funds have recently made changes to their positions in AFYA. Newfoundland Capital Management acquired a new stake in Afya during the 1st quarter worth $10,255,000. Norges Bank acquired a new stake in Afya during the 4th quarter worth $13,001,000. Jupiter Asset Management Ltd. acquired a new stake in Afya during the 1st quarter worth $5,120,000. TimesSquare Capital Management LLC boosted its stake in Afya by 31.8% during the 1st quarter. TimesSquare Capital Management LLC now owns 892,000 shares of the company's stock worth $16,582,000 after purchasing an additional 215,200 shares during the last quarter. Finally, Bamco Inc. NY raised its holdings in shares of Afya by 6.2% during the 1st quarter. Bamco Inc. NY now owns 3,567,227 shares of the company's stock worth $66,315,000 after acquiring an additional 207,766 shares during the period. 29.47% of the stock is currently owned by institutional investors.

About Afya

Afya Limited, through its subsidiaries, operates as a medical education group in Brazil. The company provides educational products and services, including medical schools, medical residency preparatory courses, graduate courses, and other programs to lifelong medical learners enrolled across its distribution network, as well as to third-party medical schools.

Featured Article: The basics of gap trading strategies

Get a free copy of the Zacks research report on Afya (AFYA)

For more information about research offerings from Zacks Investment Research, visit

Analyst Recommendations for Afya (NASDAQ:AFYA)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected]

Featured Article: Most Volatile Stocks – What Investors Need to Know to Maximize ROI

7 Stocks That Could Benefit From a Capital Gains Tax Hike

One thing every investor needs to learn is the effect of capital gains on their investments. Every time an investor sells a stock that has appreciated in value, that capital gain is subject to being taxed. Stocks that are held for less than a year pay a short-term capital gains tax rate. Stocks that are held for over a year pay a long-term capital gains tax rate.

In general, a capital gains tax hike is a bearish indicator for stocks. However, there are a couple of strategies that can help investors avoid some of the tax hit. One strategy is to keep your investments in an individual retirement account (IRA) or 401(k). However many higher-income earners want to have more access to the funds in their brokerage accounts.

A sound strategy for these investors involves buying dividend stocks. Dividend income is also taxed (unless it is reinvested), but typically when the capital gains tax rate is raised, the dividend income rate stays the same. This makes dividend stocks more attractive.

Investing in dividend stocks is never a bad idea, but at times when the capital gains tax rate is favorable, growth stocks provide a better reward for investor capital. But when long-term capital gains tax rates go up, those gains can get expensive.

In this special presentation, we’ll give you seven stocks that have a nice dividend yield and a strong story to go along with them.

View the "7 Stocks That Could Benefit From a Capital Gains Tax Hike".

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.